A review on pulmonary and mediastinal synovial sarcoma

Abstract

Sarcoma is defined as a tumor located in the thoracic cavity. However, sarcoma can occur on every side of the body. Synovial sarcoma is a rare soft tissue tumor originating from pluripotent with a high malignancy rate. The most common predilection of synovial sarcoma is in the joints. Primary synovial sarcoma of the lung and mediastinum are rare tumors and generally malignant. There are only a few cases have been reported. Definite diagnosis is made by histopathological, immunohistochemistry, and cytogenetic examination. The management strategy for synovial sarcoma requires multimodality treatment with surgery, chemotherapy, and radiotherapy. However, effective and relatively non-toxic therapy for primary synovial sarcoma is still developed. The five years life expectancy is higher if the patient received adjuvant radiotherapy and/or chemotherapy after surgery.

Radiotherapy for tumors of the mediastinum – state of the art

“…Nevertheless, retrospective analyses utilizing the Surveillance, Epidemiology, and End Results (SEER) database, along with multiple small case se-ries, have shed light on the potential benefits of adjuvant RT for specific subpopulations of patients with thymoma and thymic carcinoma. In the management of early-stage Hodgkin lymphoma, RT continues to be a crucial component of combined modality therapy, although concerns have arisen regarding late toxicity, which is dependent on the irradiated volume and radiation dose [1,2,[4][5][6][7][8][9][10].…”